🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Computer Sciences (CSC) - Elevated Vol, Bad News and Allergic IV30™

Published 01/05/2012, 04:23 AM
Updated 07/09/2023, 06:31 AM
MAR
-
OPIN
-

Computer Sciences Corporation (CSC) is engaged in the information technology (IT) and professional services industry.

I found this stock using the real-time custom scan that searches for high vols relative to the short-term and long-term historical realized vol. I've included the scan details below, but this one has a little extra pattern to it which I like.

Custom Scan Details
Stock Price GTE $7 and LTE $70
IV30™ - HV20 LTE 10
HV180 - IV30™ LTE -8
Average Option Volume GTE 1,200
Industry isNot Bio-tech
Days After Earnings GTE 10 and LTE 60

The goal with this scan is to identify short-term implied vol (IV30™) that is elevated both to the recent stock movement (HV20) and the long term trend in stock movement (HV180). I'm also looking for a reasonable amount of liquidity in the options (thus the minimum average option volume), want to avoid bio-techs (and their crazy vol) and make sure I'm not selling elevated IV30™ simply because earnings are approaching.

The CSC Charts Tab is included (below). The top portion is the stock price, the bottom is the vol (IV30™ - red vs HV20 - blue vs HV180 - pink).

csc_charts3

I've highlighted the elevated implied to the two historical realized vols. While the vol is popping today (more on that below), we can see that it's been much higher as recently as early Dec.

The stock has been headed down -- it's annual high is $55.28 and as of this writing it's trading at $24.26. The news for CSC lately has been... well it's been the kind of news you would expect for a stock that was $55 and is now $24. I've included a couple of snippets below from the last two days.

Tuesday, January 3, 2012

Fitch Ratings has put its ratings on Computer Sciences Corp on Negative Watch, citing uncertainties over its health information contract with the U.K.’s National Health Service.

Last week, Standard & Poor’s cut its long-term ratings on CSC by one notch for the same reason.

CSC last week warned it may write off as much as $1.5 billion in contract investments connected to the NHS contract, and said it would revise its 2012 forecast as a result.

Source: Washington Business Journal via Yahoo! Finance: Fitch puts CSC on watch list, written by Jeff Clabaugh.

And today CSC was mentioned in an article entitled, J.P. Morgan: Avoid these 11 stocks, written by Meena Krishnamsetty. That's probably not a good article to be listed in... just sayin'...

The specific vol comp levels are:

IV30™: 66.33%
HV20: 52.93%
HV180: 52.98%

The 52 wk range in IV30™ for CSC is [25.56%, 95.26%]. So that 66.33% level, while certainly elevated, is still only in the 58th percentile (annual).  It's also worth noting that CSC IV30™ seems to have an allergic reaction to the HV180. By that I mean, every time it gets near that level (pink line), it pops above it pretty soon after.

Let's turn to the Skew Tab, below.

csc_skew

The skew has maintained a "normal" shape. To read what "normal" skew is and why it exists you can go here: Understanding Option Skew. Feb is elevated to Jan and Mar b/c of the next earnings release which is due out around Feb 10 (ish) based on the prior two years which saw 2-10-2010 and 2-9-2011 earnings reports. One interesting point, that Jan 20 put vol is super elevated and is in fact higher than the Feb 20 puts.

Finally, let's turn to the Options Tab, for completeness.

csc_options3

While I didn't include it in the skew chart, we can see that the jun option cycle is actually priced to 54 vol -- so a significant discount to the front months. CSC usually has earning sin early Feb and late May, meaning that those Jun options have two earnings cycles embedded.

DISCLOSURE: I own puts in CSC from a calendar spread where the front expired worthless.

This is trade analysis, not a recommendation.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.